Biotechnology News

September 4, 2012

MEMPHIS, Tenn.--(BUSINESS WIRE)--Transnetyx has processed its five millionth sample, marking a significant milestone for the company and further strengthening its foothold as a leader in the molecular diagnostics field.

September 4, 2012

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--The largest pharmaceutical companies employ an average 136 medical science liaisons (MSLs) around the world, according to a new study published this month by Cutting Edge Information.

September 4, 2012

SAN DIEGO--(BUSINESS WIRE)--Critical Diagnostics announced today, Circulation, an American Heart Association Journal, released online the first study evaluating the power of ST2 to predict development of heart failure and other adverse outcomes...

September 4, 2012

BURLINGTON, Mass.--(BUSINESS WIRE)--AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the company’s mesenchymal stem cell therapy, as a potential treatment for acute kidney injury (AKI).

September 4, 2012

SAN CARLOS, Calif.--(BUSINESS WIRE)--Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded $36....

September 4, 2012

FORT COLLINS, Colo.--(BUSINESS WIRE)--Ventria Bioscience and University of Colorado at Denver to collaborate on “Therapeutic Potential of Recombinant Human Lactoferrin in the Treatment of Acetaminophen Overdose-Induced Liver Failure.”

September 4, 2012

PARAMUS, N.J.--(BUSINESS WIRE)--Proteonomix, Inc. announces agreement with a leading provider of global clinical trial technologies and services, Numoda Corporation.

September 4, 2012

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced today that the independent Data Monitoring Committee (DMC) has completed the ninth unblinded review of the LibiGel Phase III cardiovascular events and...

September 4, 2012

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a biologics license application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for approval of BAX 326, a...

September 4, 2012

DENVER--(BUSINESS WIRE)--More than 40 exhibitors will be showcasing new technologies, products and services for 500+ attendees at the 2012 BioWest, September 11, at the Marriott City Center, Denver.

September 4, 2012

EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed specialist physicians from the United States and Europe are generally...

September 4, 2012

CRANBURY, N.J.--(BUSINESS WIRE)--NJ biotech company VaxInnate Corporation hires two new executives to head Business Development and Regulatory Affairs.

September 4, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals today announced the appointment of Stuart A. Arbuckle as Executive Vice President and Chief Commercial Officer. Mr. Arbuckle has more than 25 years

September 4, 2012

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering the opening...

September 4, 2012

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that President and Chief Executive Officer Steven A. Kriegsman and Vice President of Business Development David...

September 4, 2012

CONCORD, Calif.--(BUSINESS WIRE)--Ilex, Cerus’ exclusive distributor for South Africa, has submitted a regulatory dossier for approval of INTERCEPT platelets under a fast track designation by MCC, South African regulatory authority.

September 4, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, today announced its participation in four upcoming conferences.

September 4, 2012

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, president and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference...

September 4, 2012

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has reached agreement with Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), to settle pending U.S. litigation with regard to the production...

September 4, 2012

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Scynexis Inc. has entered into an exclusive license agreement with Dechra Pharmaceuticals PLC for the development and commercialization of SCY-641 for treatment of canine dry eye.

September 4, 2012

SHANGHAI & PALO ALTO, Calif.--(BUSINESS WIRE)--WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, and Open...

September 4, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV)...

September 4, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the following upcoming conferences: Rodman & Renshaw Annual Global Investment Conference – New York City, September 10, 2012, at 4:55 p.m....

September 4, 2012

AUSTIN, Texas--(BUSINESS WIRE)--LDR, a privately held medical device company offering innovative spinal implants for both non-fusion and fusion applications, announced that it has received 510(k) clearance from the United States Food and Drug...

September 4, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus initiated the first of two Phase 2a clinical studies with Z160, its first-in-class, state-dependent, N-type calcium channel blocker for the treatment of chronic neuropathic pain.

September 4, 2012

NEW YORK--(BUSINESS WIRE)--Manhattan Research’s Digital MedTech Physician™ covers how physicians use digital channels to learn about medical devices – Webinar September 5th

September 4, 2012

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today provided an update on its strategic business...

September 4, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business at two upcoming investor...

September 4, 2012

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Codexis, Inc. (NASDAQ: CDXS), a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals and pharmaceuticals, today announced the appointment of David O’Toole as Senior Vice...

September 4, 2012

OSAKA, Japan & BEDMINSTER, N.J.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502, “Takeda”) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP, “NPS”), jointly announced today that the European Commission (EC) has granted European...

September 4, 2012

LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix announced top line results from a clinical study: novel inhaled therapeutic, PUR118, demonstrated anti-inflammatory efficacy and was well-tolerated in chronic obstructive pulmonary disease.

September 4, 2012

LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix announced the appointment of Robert Clarke, Ph.D., as Chief Executive Officer.

September 4, 2012

YOKOHAMA, Japan--(BUSINESS WIRE)--The Netzsch Analyzing & Testing division and Bruker Corporation today announced jointly that Netzsch Japan K.K. has acquired Bruker’s Thermal Analysis instruments business in Japan. Together with the well-...

September 4, 2012

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the following...

September 4, 2012

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that it will webcast the Company’s presentations at two upcoming investment conferences. Illumina will webcast its presentation at the Morgan Stanley Global Healthcare...

September 4, 2012

LONDON--(BUSINESS WIRE)--New study “Future Horizons in the Global Immunodiagnostics Market: Supplier Shares and Sales Forecasts” elaborated by Venture Planning Group has been recently published by Market Publishers Ltd.

September 4, 2012

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA® (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney...

September 4, 2012

PORTLAND, Ore.--(BUSINESS WIRE)--HemCon Medical Technologies (“HemCon”), a leading global developer of advanced medical technologies and products, announced receiving an additional U.S. regulatory clearance for the antimicrobial hemostatic IV...

September 4, 2012

LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced the completion of enrollment in two pivotal U.S. and Canadian Phase III clinical trials of ATX-101, a potential first-in-class injectable facial aesthetic...

September 4, 2012

CHALFONT ST. GILES, England--(BUSINESS WIRE)--GE Healthcare, the healthcare business of GE (NYSE: GE), today introduced KUBioTM, an innovative off-the-shelf, modular factory designed to save manufacturers of biopharmaceuticals both time and money...

September 4, 2012

LONDON--(BUSINESS WIRE)--Exoskeleton technology leader, ARGO Medical Technologies, along with mobility solutions provider, Cyclone Technologies, announced today that Claire Lomas has become the first person to take home an exoskeleton system for...

September 4, 2012

TORRANCE, Calif.--(BUSINESS WIRE)--The CEO of Phenomenex, Fasha Mahjoor, successfully rappelled/abseiled down 87 floors of the Shard in London, Europe's tallest building, to raise money for The Outward Bound Trust educational charity.